That's so interesting, thank you Rich!
What do you think would be the best strategy to deal with this problem?
- Take digestive enzymes (eg. Kirkman "DPPIV Forte") - problem is how much, and how long before eating?
- Take glutathione - but can it be absorbed when taken orally?
- Take cysteine as well?
- Just avoid dairy and gluten altogether?
My son has CFS and Lyme with mild/periodic autism symptoms. The autism used to be full blown and fairly severe - he was unable to understand speech at age 3 and just played with spinning things all the time etc. I achieved a drastic improvement in him by removing gluten and dairy from his diet and many other foods too, but now he eats all except these two foods.
His gastroenterologist has suggested trying him on dairy and gluten again, partly for nutritional purposes. The Lyme doctor has said a good proportion of children with Lyme don't have gluten adn dairy problems, or intestinal type symptoms anyway, so as far as he is concerned it wold be alright to test it. However I am wary. My son has been on antibiotic treatment for his Lyme disease for 6 months and there have been spectacular improvements in all his formerly catastrophic intestinal and allergy symptoms, but I am not convinced that means he can handle gluten or dairy yet.
I would really appreciate your advice on how you would approach this and whether you think it is worth experimenting.
He is 5 years old BTW, so he can explain symptoms to me such as pain, but if he got problems like brain fog for example he wouldn't know how to explain that.
Hi, Athene.
Well, as you know, I'm a researcher and not a licensed physician, so I cannot give individual treatment advice unless a physician is on board to evaluate my suggestions in the light of the particular case. However, I can talk about where the hypothesis would point. If it is correct, then raising the level of glutathione in the cells should help. For about 5 years, from 1999 through 2004, I encouraged PWCs to boost their glutathione levels in various direct ways. This seemed to help most of them, on a temporary basis, but if they stopped, their symptoms worsened again, so it wasn't a permanent fix. On the other hand, there were others who could not tolerate the glutathione boosting, and we kicked around several possible explanations for that, including mobilization of toxins and killing of pathogens as a result of better function of the immune system and the detoxication system, also including an increase in cysteine levels to the point that auto-oxidation of cysteine was increasing the oxidative stress, also including an increase in sulfite because of overloading of the sulfite oxidase enzyme, and most recently, a deficiency of vitamins B2 and/or B3, which are needed to recycle glutathione when it becomes oxidized.
I still don't know for sure which if any of these is the explanation for the glutathione intolerance in some PWCs. Testing shows that they are low in it, but giving it directly just doesn't work for some.
In late 2004, S. Jill James et al. published some research in autism that indicated that glutathione is also low in that disorder, and in addition, there is a problem with the methylation cycle, which is upstream of glutathione synthesis in the sulfur metabolism. They found that treating to lift a partial block in the methylation cycle caused glutathione to come up automatically, without direct boosting. I suspected that the same might be true in ME/CFS, and that has proven to be true, based on lab testing and treatment experience. So now I recommend treating the partial methylation cycle block, and that has been more successful. There are several methylation protocols in use now, and I don't know which is the best. One of them is the so-called Simplified Treatment Approach that I have suggested, and which was recently revised in March, 2011. It has been posted on another thread, in the Methylation forum.
If glutathione is to be given directly, I now favor using the liposomal forms. If tolerated, I think this is about the best direct way to raise glutathione in the tissues, at least temporarily, and it may help with the DPPIV deficiency, but I don't have any clinical data to back this up. If that is not tolerated, treating the more fundamental issue with the methylation cycle should raise glutathione on a more permanent basis.
Digestive enzymes containing DPPIV should be helpful, on a temporary basis. I note that there is a study published from Stanford University that found that a combination of DPPIV and another enzyme from Aspergillus seemed to be more effective in breaking down gluten, but I don't know if this combination is commercially available. The abstract is pasted below, and the full paper is available free at PubMed, by typing the PBID number in the search box, and then clicking on the symbol at the upper right.
Taking cysteine as L-cysteine is generally not such a good idea, because it can become toxic at high enough dosages, I think because of its tendency to auto-oxidize, contributing to oxidative stress. N-acetylcysteine is a safer form, but if there is a high body burden of mercury, Dr. David Quig of Doctor's Data Lab has written that the dosage should be limited to 300 mg per day to avoid moving mercury into the brain.
Of course, avoiding dairy and gluten will work, too, but as you are probably more aware than I am, this is not an easy diet to maintain.
My hope is that in the long run, fixing the partial methylation cycle block so that glutathione comes up to normal will end up fixing this problem as well as many others in ME/CFS as well as in the autism spectrum. We are finding that it is not the magic bullet for a complete treatment, because of other issues that arose before onset or that accumulated after onset, but it does deal with the vicious circle mechanism that appears to be at the heart of the pathophysiology of these disorders, in my opinion.
Best regards,
Rich
PLoS One. 2009 Jul 21;4(7):e6313.
A food-grade enzyme preparation with modest gluten detoxification properties.
Ehren J, Morn B, Martin E, Bethune MT, Gray GM, Khosla C.
Source
Department of Chemical Engineering, Stanford University, Stanford, CA, USA.
Abstract
BACKGROUND AND AIMS:
Celiac sprue is a life-long disease characterized by an intestinal inflammatory response to dietary gluten. A gluten-free diet is an effective treatment for most patients, but accidental ingestion of gluten is common, leading to incomplete recovery or relapse. Food-grade proteases capable of detoxifying moderate quantities of dietary gluten could mitigate this problem.
METHODS:
We evaluated the gluten detoxification properties of two food-grade enzymes, aspergillopepsin (ASP) from Aspergillus niger and dipeptidyl peptidase IV (DPPIV) from Aspergillus oryzae. The ability of each enzyme to hydrolyze gluten was tested against synthetic gluten peptides, a recombinant gluten protein, and simulated gastric digests of whole gluten and whole-wheat bread. Reaction products were analyzed by mass spectrometry, HPLC, ELISA with a monoclonal antibody that recognizes an immunodominant gluten epitope, and a T cell proliferation assay.
RESULTS:
ASP markedly enhanced gluten digestion relative to pepsin, and cleaved recombinant alpha2-gliadin at multiple sites in a non-specific manner. When used alone, neither ASP nor DPPIV efficiently cleaved synthetic immunotoxic gluten peptides. This lack of specificity for gluten was especially evident in the presence of casein, a competing dietary protein. However, supplementation of ASP with DPPIV enabled detoxification of moderate amounts of gluten in the presence of excess casein and in whole-wheat bread. ASP was also effective at enhancing the gluten-detoxifying efficacy of cysteine endoprotease EP-B2 under simulated gastric conditions.
CONCLUSIONS:
Clinical studies are warranted to evaluate whether a fixed dose ratio combination of ASP and DPPIV can provide near-term relief for celiac patients suffering from inadvertent gluten exposure. Due to its markedly greater hydrolytic activity against gluten than endogenous pepsin, food-grade ASP may also augment the activity of therapeutically relevant doses of glutenases such as EP-B2 and certain prolyl endopeptidases.
PMID:
19621078